Monoclonal antibodies in cancer therapy: 25 years of progress.
Oldham
Robert K
RK
Dillman
Robert O
RO
D000074323:Alemtuzumab; D000818:Animals; D000911:Antibodies, Monoclonal / Q000266:history* / Q000627:therapeutic use* / Q000633:toxicity; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000266:history / Q000627:therapeutic use / Q000633:toxicity; D000068258:Bevacizumab; D004195:Disease Models, Animal; D005544:Forecasting; D049673:History, 20th Century; D006801:Humans; D007167:Immunotherapy / Q000639:trends; D009369:Neoplasms / Q000188:drug therapy*; D000069283:Rituximab; D000068878:Trastuzumab
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D058846:Antibodies, Monoclonal, Murine-Derived; D000912:Antibodies, Neoplasm; D000970:Antineoplastic Agents; D000068258:Bevacizumab; D000074323:Alemtuzumab; D000069283:Rituximab; D000068878:Trastuzumab